CARA THERAPEUTICS INC (CARA)

US1407551092 - Common Stock

0.4226  +0.01 (+3.35%)

After market: 0.4089 -0.01 (-3.24%)

Fundamental Rating

3

Overall CARA gets a fundamental rating of 3 out of 10. We evaluated CARA against 193 industry peers in the Pharmaceuticals industry. The financial health of CARA is average, but there are quite some concerns on its profitability. CARA is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

CARA had negative earnings in the past year.
CARA had a negative operating cash flow in the past year.
In the past 5 years CARA reported 4 times negative net income.
In the past 5 years CARA always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -186.10%, CARA is doing worse than 87.96% of the companies in the same industry.
CARA's Return On Equity of -13511.32% is on the low side compared to the rest of the industry. CARA is outperformed by 87.43% of its industry peers.
Industry RankSector Rank
ROA -186.1%
ROE -13511.32%
ROIC N/A
ROA(3y)-58.96%
ROA(5y)-43.89%
ROE(3y)-100.1%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 170.32%, CARA belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
CARA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 170.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

CARA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CARA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CARA has more shares outstanding
There is no outstanding debt for CARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CARA has an Altman-Z score of -24.21. This is a bad value and indicates that CARA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -24.21, CARA is doing worse than 87.96% of the companies in the same industry.
CARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.21
ROIC/WACCN/A
WACC9.6%

2.3 Liquidity

CARA has a Current Ratio of 4.77. This indicates that CARA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.77, CARA is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
A Quick Ratio of 4.71 indicates that CARA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.71, CARA is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.71

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.60% over the past year.
CARA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.22%.
The Revenue has been growing by 9.21% on average over the past years. This is quite good.
EPS 1Y (TTM)18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.77%
Revenue 1Y (TTM)-59.22%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-47.47%

3.2 Future

The Earnings Per Share is expected to grow by 11.48% on average over the next years. This is quite good.
The Revenue is expected to grow by 13.12% on average over the next years. This is quite good.
EPS Next Y39.95%
EPS Next 2Y28.05%
EPS Next 3Y19.43%
EPS Next 5Y11.48%
Revenue Next Year-75.83%
Revenue Next 2Y-51.58%
Revenue Next 3Y-35.75%
Revenue Next 5Y13.12%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CARA. In the last year negative earnings were reported.
Also next year CARA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CARA's earnings are expected to grow with 19.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.05%
EPS Next 3Y19.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CARA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARA THERAPEUTICS INC

NASDAQ:CARA (12/20/2024, 8:00:01 PM)

After market: 0.4089 -0.01 (-3.24%)

0.4226

+0.01 (+3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners32.75%
Inst Owner Change-22.31%
Ins Owners2.07%
Ins Owner Change-0.25%
Market Cap23.18M
Analysts48.89
Price Target1.03 (143.73%)
Short Float %1.25%
Short Ratio0.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.9%
Min EPS beat(2)-32.39%
Max EPS beat(2)8.59%
EPS beat(4)1
Avg EPS beat(4)-25.54%
Min EPS beat(4)-40.4%
Max EPS beat(4)8.59%
EPS beat(8)3
Avg EPS beat(8)-21.19%
EPS beat(12)5
Avg EPS beat(12)-9.66%
EPS beat(16)8
Avg EPS beat(16)19.79%
Revenue beat(2)1
Avg Revenue beat(2)18.9%
Min Revenue beat(2)-17.21%
Max Revenue beat(2)55%
Revenue beat(4)2
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-68.74%
Max Revenue beat(4)55%
Revenue beat(8)4
Avg Revenue beat(8)-14.3%
Revenue beat(12)7
Avg Revenue beat(12)-7.93%
Revenue beat(16)9
Avg Revenue beat(16)-0.79%
PT rev (1m)0.33%
PT rev (3m)-57.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25.49%
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)22.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.67
P/FCF N/A
P/OCF N/A
P/B 32.79
P/tB 32.79
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS0.16
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.1%
ROE -13511.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 170.32%
FCFM N/A
ROA(3y)-58.96%
ROA(5y)-43.89%
ROE(3y)-100.1%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1144.28%
Cap/Sales 35.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.71
Altman-Z -24.21
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)316.33%
Cap/Depr(5y)225.13%
Cap/Sales(3y)3.87%
Cap/Sales(5y)2.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.77%
EPS Next Y39.95%
EPS Next 2Y28.05%
EPS Next 3Y19.43%
EPS Next 5Y11.48%
Revenue 1Y (TTM)-59.22%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-47.47%
Revenue Next Year-75.83%
Revenue Next 2Y-51.58%
Revenue Next 3Y-35.75%
Revenue Next 5Y13.12%
EBIT growth 1Y33.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.83%
EBIT Next 3Y12.76%
EBIT Next 5Y8.58%
FCF growth 1Y-36.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.47%
OCF growth 3YN/A
OCF growth 5YN/A